First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study.

Worthley, Stephen G; Abizaid, Alexandre; Kirtane, Ajay J; Simon, Daniel I; Windecker, Stephan; Brar, Sandeep; Meredith, Ian T; Shetty, Sharad; Sinhal, Ajay; Almonacid, Alexandra Popma; Chamié, Daniel; Maehara, Akiko; Stone, Gregg W (2017). First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study. JACC. Cardiovascular Interventions, 10(2), pp. 147-156. Elsevier 10.1016/j.jcin.2016.10.020

[img] Text
1-s2.0-S193687981631843X-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (940kB) | Request a copy

OBJECTIVES This study sought to assess the safety and effectiveness of the drug-filled stent (DFS) (Medtronic, Santa Rosa, California) in the treatment of patients with coronary artery disease. BACKGROUND Polymer-free drug-eluting stents have the potential to improve clinical outcomes and facilitate shorter durations of dual antiplatelet therapy. The polymer-free DFS is made from a trilayered continuous wire with an outer cobalt chromium layer, a middle tantalum layer, and an inner lumen coated with sirolimus. Small laser-drilled holes on the abluminal stent surface control drug elution. METHODS The RevElution trial enrolled 100 patients with de novo coronary lesions 2.25 to 3.50 mm in diameter and length ≤27 mm in 2 cohorts of 50 patients for angiographic, intravascular ultrasound, and clinical assessment at 9 or 24 months, with optical coherence tomography performed in a subset of 30 patients at each time period. The primary endpoint was angiographic in-stent late lumen loss at 9 months compared with Resolute zotarolimus-eluting stent (Medtronic) historical control data. RESULTS Fifty patients with 56 lesions were treated with DFS in the 9-month cohort. In-stent late lumen loss was 0.26 ± 0.28 mm for DFS and 0.36 ± 0.52 mm for Resolute (pnoninferiority <0.001). The binary angiographic restenosis rate was 0%. Median stent strut coverage by optical coherence tomography was 91.4%, 95.6%, and 99.1% at 1, 3, and 9 months, respectively. One non-Q-wave myocardial infarction occurred, with a 9-month target lesion failure rate of 2.1%. No stent thrombosis occurred. CONCLUSIONS At 9 months, the polymer-free DFS was safe and effective with high rates of early strut coverage and noninferior late lumen loss compared to Resolute. (Medtronic RevElution Trial [RevElution]; NCT02480348).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1876-7605

Publisher:

Elsevier

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

12 Feb 2018 14:39

Last Modified:

12 Feb 2018 14:39

Publisher DOI:

10.1016/j.jcin.2016.10.020

PubMed ID:

28104208

Uncontrolled Keywords:

drug-eluting stent(s) drug-filled stent(s) percutaneous coronary intervention polymer-free stent

BORIS DOI:

10.7892/boris.111107

URI:

https://boris.unibe.ch/id/eprint/111107

Actions (login required)

Edit item Edit item
Provide Feedback